AN2 Therapeutics, Inc. (ANTX) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.8x

Market Cap

$222.27M

MomentumView details →

1D Return

−1.01%

YTD Return

+415.79%

RSI (14)

56.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.8x

Market Cap

$222.27M

RSI (14)

56.5

MomentumView details →

1D Return

−1.01%

YTD Return

+415.79%

SummaryUpdated Jun 1, 2026

AN2 Therapeutics, Inc. (NASDAQ:ANTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Menlo Park, California. The company went public in March 2022 and focuses on developing innovative treatments for rare, chronic, and serious infectious diseases. AN2 Therapeutics is currently advancing its lead drug candidate through clinical trials, representing a specialized approach to addressing unmet medical needs in the infectious disease space.

Ask drillr about AN2 Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.78%

ROA (TTM)

−44.41%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+13.71%

FCF YoY

+13.58%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+32.56%

EBITDA YoY

−30.08%

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

25.00%

Beats (12Q)

2/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

−14.18%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

14.32x

Quick Ratio

14.32x

Div Yield

—

Div Rate

—

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−36.28M

Op. CF (TTM)

−30.68M

Next earningsNov 5, 2026 →

Latest newsMore news →

No recent news for ANTX.

Similar companies

Keros Therapeutics, Inc.KROS Coherus Oncology, Inc.CHRS Tonix Pharmaceuticals Holding Corp.TNXP Sol-Gel Technologies Ltd.SLGL Immunotech Biopharm Ltd06978.HK Voyager Therapeutics, Inc.VYGR Find similar companies →

Latest newsMore news →

No recent news for ANTX.